NCT00717782

Brief Summary

Thrombosed external haemorrhoids are one of the most frequent anorectal emergencies. They are associated with swelling and intense pain. This study evaluated the efficacy and safety of an intersphincteric injection of botulinum toxin for pain relief in patients with thrombosed external haemorrhoids

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Jan 2003

Typical duration for phase_4

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2003

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2005

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2006

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

July 16, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 18, 2008

Completed
Last Updated

July 18, 2008

Status Verified

July 1, 2008

Enrollment Period

2.9 years

First QC Date

July 16, 2008

Last Update Submit

July 17, 2008

Conditions

Keywords

botulinum toxinthrombosed external haemorrhoidspain

Outcome Measures

Primary Outcomes (1)

  • evaluate the efficacy and safety of intrasphincteric injection of botulinum toxin for pain relief in patients with Thrombosed External Haemorrhoids.

    1

Secondary Outcomes (1)

  • evaluate the absence of side-effects and the simplicity of application

    1

Study Arms (2)

1

EXPERIMENTAL

Patients were injected with 0·6 ml of a solution containing 30 units botulinum toxin A (Botox; Allergan, Ireland). A 27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter.

Procedure: injection of botulinum toxin

2

PLACEBO COMPARATOR

Patients in the placebo group received a 0·6-ml injection of saline. A27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter.

Procedure: injection of saline

Interventions

Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter

Also known as: botox injection
1

Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter

Also known as: saline injection
2

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • thrombosed external haemorrhoids disease
  • patients that refused surgery for fear of procedure related pain.

You may not qualify if:

  • previous anal surgery
  • third- and fourth-degree haemorrhoids
  • anal fissure
  • anal fistula
  • presumed or confirmed pregnancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Patti R, Arcara M, Bonventre S, Sammartano S, Sparacello M, Vitello G, Di Vita G. Randomized clinical trial of botulinum toxin injection for pain relief in patients with thrombosed external haemorrhoids. Br J Surg. 2008 Nov;95(11):1339-43. doi: 10.1002/bjs.6236.

MeSH Terms

Conditions

Pain

Interventions

Botulinum Toxins, Type ASodium Chloride

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Botulinum ToxinsMetalloendopeptidasesEndopeptidasesPeptide HydrolasesHydrolasesEnzymesEnzymes and CoenzymesMetalloproteasesBacterial ProteinsProteinsAmino Acids, Peptides, and ProteinsBacterial ToxinsToxins, BiologicalBiological FactorsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Gaetano Di Vita

    A.O.U.P.

    PRINCIPAL INVESTIGATOR
  • Rosalia Patti

    A.O.U.P.

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 16, 2008

First Posted

July 18, 2008

Study Start

January 1, 2003

Primary Completion

December 1, 2005

Study Completion

January 1, 2006

Last Updated

July 18, 2008

Record last verified: 2008-07